IP Library Granted Patent US 8,957,111
Granted Patent B2
US 8,957,111 · App. 13/764,709 · Granted Feb 17, 2015

Strontium (M) ascorbate, compositions containing same, method for making same and method of using same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,957,111
App. No.
13/764,709
Granted
Feb 17, 2015
Kind
B2
Abstract

A compound of formula (ascorbate) 2 Sr:(M +a ) x (ascorbate) y , or ascorbate) 2 Sr:Ca(ascorbate) 2 , a composition containing the same, a method of making the same and a method of administering the same as a supplement.

Claims (24)

1. A compound of formula (1):

(ascorbate) 2 Sr:(M +a ) x (ascorbate) y

wherein ascorbate refers to the ascorbate anion:

wherein y is a positive integer, wherein x is a positive integer, wherein a is a positive integer reflecting the valence of M;

wherein (y)=((x) multiplied by (+a)) such that a total positive charge ((x) multiplied by (+a)) equals a total negative charge (y) provided that the ascorbate anion has a negative valence of (−1); and

wherein M is an alkali metal, an alkali earth metal or Mn, Cu, Zn, Fe and a combination thereof.

2. The compound of claim 1 , wherein M is selected from the group consisting of Na, K, M, Ca, Mn, Cu, Zn, Fe and combinations thereof, wherein y is 1, 2, 3, 4, 5, or 6, wherein a is 1, 2, 3, 4, 5, or 6, and wherein x is 1, 2, 3, 4, 5, or 6.

3. The compound of claim 1 of formula (2):

(ascorbate) 2 Sr:Ca(ascorbate) 2

wherein Sr refers to strontium and Ca refers to calcium.

4. The compound of claim 1 , wherein the ratio of the moles of Sr to the moles of M is selected from the group consisting of, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.25, 2.5, 2.75, 3, and 4.

5. The compound of claim 3 , wherein the ratio of the moles of Sr to the moles of Ca is selected from the group consisting of, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.25, 2.5, 2.75, 3, and 4.

6. A composition comprising the compound of formula (1) of claim 1 and a pharmaceutically acceptable excipient.

7. The composition of claim 6 in an oral dosage form selected from the group consisting of a tablet, a capsule, a softgel capsule, a liquid, a syrup, a suspension, a sublingual tablet, a powder, and a lozenge.

8. The composition of claim 7 wherein the oral dosage form is an immediate release dosage form or an extended release dosage form.

9. A composition comprising the compound of formula (2) of claim 3 and a pharmaceutically acceptable excipient.

10. The composition of claim 9 in an oral dosage form selected from the group consisting of a tablet, a capsule, a softgel capsule, a liquid, a syrup, a suspension, a sublingual tablet, a powder, and a lozenge.

11. The composition of claim 10 wherein the oral dosage form is an immediate release dosage form or an extended release dosage form.

12. A method of providing ascorbic acid comprising administering the composition of claim 6 to a subject.

13. The method of claim 12 wherein the subject is in need of the composition of claim 6 and the subject is a human.

14. A method of providing ascorbic acid comprising administering the composition of claim 9 to a subject.

15. The method of claim 14 wherein the subject is in need of the composition of claim 6 and the subject is a human.

16. The compound of claim 1 in a solid form selected from the group consisting of a powder form, a granular form or a cake form.

17. The compound of claim 1 , wherein a ratio of the moles of strontium to the moles of M is such that strontium is present in an amount that is more than or equal to the amount of M.

Assignments (5)
SECURITY INTEREST Recorded Sep 30, 2020
From: NUTRACEUTICAL CORPORATION
To: OWL ROCK CAPITAL CORPORATION
Reel/Frame 053929/0115 →
RELEASE OF SECURITY INTEREST Recorded Sep 30, 2020
From: THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY
To: NUTRACEUTICAL CORPORATION; NUTRAMARKS, INC.
Reel/Frame 053939/0543 →
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL AT R/F 043662/0796 Recorded Sep 30, 2020
From: ANTARES CAPITAL LP, AS COLLATERAL AGENT
To: NUTRACEUTICAL CORPORATION
Reel/Frame 054209/0003 →
FIRST LIEN PATENT SECURITY AGREEMENT Recorded Aug 24, 2017
From: NUTRACEUTICAL CORPORATION
To: ANTARES CAPITAL LP, AS COLLATERAL AGENT
Reel/Frame 043662/0796 →
SECURITY INTEREST Recorded Aug 23, 2017
From: NUTRACEUTICAL CORPORATION; NUTRAMARKS, INC.
To: THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY
Reel/Frame 043376/0256 →